Perseus Proteomics

Perseus Proteomics Inc. is a Japanese biotechnology company, publicly traded on the Tokyo Stock Exchange, specializing in the research and development of antibody-based therapeutics. Established on February 1, 2001, the company was incubated at the University of Tokyo, founded upon the protein expression and antibody generation technologies developed by the Research Center for Advanced Science and Technology.

The firm's operations are segmented into three core areas: its primary drug discovery business, antibody research support services, and the sale of antibody and reagent products. The drug discovery division focuses on creating new medical drugs, typically advancing them through Phase I/IIa clinical trials before licensing them out to larger pharmaceutical companies for late-stage development and commercialization. This business model generates revenue through upfront fees, milestone payments tied to development progress, and post-approval royalties. The antibody research support unit provides services like antibody generation and sequence analysis, leveraging the expertise from its own drug discovery activities. The company also commercializes a portfolio of approximately 100 antibody products and ELISA kits for research purposes, including a comprehensive set targeting all 48 human nuclear receptors.

Perseus Proteomics' therapeutic pipeline includes several candidates targeting various forms of cancer. Notable products are PPMX-T002, targeting cadherin 3 (CDH3), and PPMX-T003, which targets the transferrin receptor (TfR). The company utilizes advanced techniques to develop these monoclonal antibodies, including the hybridoma method and the Nobel Prize-winning phage display method, which allows for the creation of human antibodies in vitro. Its current President and CEO is Takuya Yokokawa.

Keywords: antibody therapeutics, drug discovery, biotechnology, oncology, monoclonal antibodies, clinical trials, pharmaceutical licensing, proteomics, research reagents, cancer therapy